IL316410A - Blumosodil for the treatment of chronic pulmonary allograft dysfunction - Google Patents

Blumosodil for the treatment of chronic pulmonary allograft dysfunction

Info

Publication number
IL316410A
IL316410A IL316410A IL31641024A IL316410A IL 316410 A IL316410 A IL 316410A IL 316410 A IL316410 A IL 316410A IL 31641024 A IL31641024 A IL 31641024A IL 316410 A IL316410 A IL 316410A
Authority
IL
Israel
Prior art keywords
belumosudil
treating chronic
chronic lung
lung allograft
allograft dysfunction
Prior art date
Application number
IL316410A
Other languages
English (en)
Hebrew (he)
Original Assignee
Kadmon Corp Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corp Llc filed Critical Kadmon Corp Llc
Publication of IL316410A publication Critical patent/IL316410A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL316410A 2022-04-19 2023-04-18 Blumosodil for the treatment of chronic pulmonary allograft dysfunction IL316410A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263332628P 2022-04-19 2022-04-19
US202263389444P 2022-07-15 2022-07-15
PCT/US2023/018952 WO2023205153A1 (en) 2022-04-19 2023-04-18 Belumosudil for treating chronic lung allograft dysfunction

Publications (1)

Publication Number Publication Date
IL316410A true IL316410A (en) 2024-12-01

Family

ID=86330932

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316410A IL316410A (en) 2022-04-19 2023-04-18 Blumosodil for the treatment of chronic pulmonary allograft dysfunction

Country Status (11)

Country Link
US (1) US20250255867A1 (cg-RX-API-DMAC7.html)
EP (1) EP4511036A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513240A (cg-RX-API-DMAC7.html)
KR (1) KR20250003657A (cg-RX-API-DMAC7.html)
CN (1) CN119031914A (cg-RX-API-DMAC7.html)
AU (1) AU2023256541A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249201A1 (cg-RX-API-DMAC7.html)
IL (1) IL316410A (cg-RX-API-DMAC7.html)
MX (1) MX2024012802A (cg-RX-API-DMAC7.html)
TW (1) TW202404602A (cg-RX-API-DMAC7.html)
WO (1) WO2023205153A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102993352B1 (ko) 2019-12-20 2026-07-22 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
AU2024292378A1 (en) * 2023-07-17 2026-03-05 Kadmon Corporation, Llc Combination therapy comprising btk inhibitor and belumosudil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
RS63503B1 (sr) 2012-10-05 2022-09-30 Kadmon Corporation Llc Inhibitori rho kinaze
US11311541B2 (en) * 2014-04-09 2022-04-26 Kadmon Corporation, Llc Treatment of GVHD

Also Published As

Publication number Publication date
TW202404602A (zh) 2024-02-01
CN119031914A (zh) 2024-11-26
AU2023256541A1 (en) 2024-12-05
KR20250003657A (ko) 2025-01-07
AU2023256541A2 (en) 2024-12-12
EP4511036A1 (en) 2025-02-26
JP2025513240A (ja) 2025-04-24
US20250255867A1 (en) 2025-08-14
MX2024012802A (es) 2024-11-08
WO2023205153A1 (en) 2023-10-26
CA3249201A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
IL285999A (en) jak1 inhibitor pathway for the treatment of impaired chronic lung allograft function
GB202306469D0 (en) Methods
CA224620S (en) Lighter
GB202210325D0 (en) Methods
GB202205881D0 (en) Methods
IL320896A (en) Methods for treating or preventing transthyretin-mediated amyloidosis
PT3510167T (pt) Métodos e composições para prever disfunção crónica de aloenxerto pulmonar
PL4048284T4 (pl) Metoda leczenia nowotworów
HK40122725A (en) Belumosudil for treating chronic lung allograft dysfunction
PT3645735T (pt) Métodos e composições para prever disfunção crónica de aloenxerto pulmonar
HUE062596T2 (hu) Anyag felület-erõsítõ kezeléshez
IL304221A (en) A method for treating chronic kidney diseases
GB202217332D0 (en) Methods
HK40067155A (en) Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
CA219209S (en) Lighter
SMT202200103T1 (it) Metodo di fabbricazione di pannelli in legno massiccio multistrato
CA223145S (en) Weir
CA223136S (en) Weir
CA217503S (en) Pool
CA213070S (en) Pool cue canister
GB2628034B (en) Finishing apparatus
GB2634272B (en) Methods
CA232489S (en) Straight rail
GB202316617D0 (en) Formation method
GB202405283D0 (en) Decking